论文部分内容阅读
目的:观察巴曲酶联合依达拉奉治疗急性脑梗死的效果。方法:选择急性期脑梗死160例,随机分为观察组和对照组各80例。对照组给予急性脑梗死常规治疗及静脉滴注巴曲酶注射液;观察组在对照组治疗基础上,给予依达拉奉注射液静脉滴注。比较两组入院时及治疗后第3天、第7天、第14天血浆溶血磷脂酸(LPA)和纤维蛋白原(Fig)水平、神经功能缺损评分;分别于入院时和治疗后第14天,采用颅脑CT灌注成像法测定患者脑血流量、脑容量。结果:入院后第3天、第7天、第14天,两组LPA及Fig水平、神经功能缺损评分分值均显著或非常显著低于入院时(P<0.05);第3天、第7天,观察组LPA及Fig水平显著低于对照组(P<0.05);第3天、第7天、第14天,观察组神经功能缺损评分分值显著低于对照组(P<0.05)。治疗后,两组血黏度均显著或非常显著降低,观察组显著低于对照组(P<0.05,P<0.01);两组脑容量及脑血流量均显著高于治疗前,观察组显著高于对照组(P<0.05)。结论:巴曲酶联合依达拉奉治疗急性脑梗死,可降低血浆LPA和Fig水平,改善血黏度和脑血流量,减轻神经功能缺损。
Objective: To observe the effect of batroxobin and edaravone in the treatment of acute cerebral infarction. Methods: 160 cases of acute cerebral infarction were randomly divided into observation group and control group of 80 cases. The control group was given routine treatment of acute cerebral infarction and intravenous batroxobin injection; the observation group was given intravenous infusion of edaravone on the basis of the control group. The levels of plasma LPA and fibrinogen (Fig) and neurological deficit scores on admission and on the 3rd, 7th and 14th day after treatment were compared between the two groups on admission and on the 14th day after treatment Brain perfusion and brain volume were measured by brain CT perfusion imaging. Results: On the third, seventh and fourteenth days after admission, the scores of LPA and Fig and neurological deficit scores of both groups were significantly or very significantly lower than those on admission (P <0.05); on the third day, Day, the levels of LPA and Fig in the observation group were significantly lower than those in the control group (P <0.05). On the 3rd, 7th and 14th days, the score of neurological deficit in the observation group was significantly lower than that of the control group (P <0.05). After treatment, the blood viscosity of both groups were significantly or very significantly reduced, the observation group was significantly lower than the control group (P <0.05, P <0.01); both brain volume and cerebral blood flow were significantly higher than before treatment, the observation group was significantly higher In the control group (P <0.05). Conclusion: Batroxobin combined with edaravone in the treatment of acute cerebral infarction can reduce plasma LPA and Fig levels, improve blood viscosity and cerebral blood flow, reduce neurological deficits.